Innovation Ed
TRISCEND II trial: TTVR vs. optimal medical therapy for severe tricuspid regurgitation – #TCT2024
Video by PCR via YouTube
Go to Source
Alex Sticchi interviews Susheel K. Kodali about the results of the TRISCEND II trial which he presented with Suzanne V. Arnold at TCT 2024 in Washington.
In summary, the TRISCEND II trial underscores TTVR as a valuable option for symptomatic relief in severe TR patients who are not surgical candidates, marking an advancement in TR treatment. However, careful patient selection, shared decision-making, and ongoing monitoring of long-term outcomes are essential as #TTVR finds its place in clinical practice.
More news about the TCT 2024 on PCRonline: https://www.pcronline.com/News/Whats-new-on-PCRonline/2024/TCT/PCRonline-at-TCT-2024